Published online September 1, 2004
PEDIATRICS Vol. 114 No. 3 September 2004, pp. 899-900 (doi:10.1542/peds.2004-0752)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clandinin, M. T.
Right arrow Articles by Koo, W. W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clandinin, M. T.
Right arrow Articles by Koo, W. W. K.
Related Collections
Right arrow Nutrition & Metabolism

Reduced Bone Mineralization in Infants Fed Palm Olein-Containing Formula: A Randomized, Double-Blinded, Prospective Trial

Michael T. Clandinin, PhD
Agricultural, Food, and Nutritional Sciences,
University of Alberta,
Edmonton, AB, Canada T6G 2H1

Bodil Larsen, BSc, RD
Neonatal and Pediatric Intensive Care,
Stollery Children’s Hospital,
Edmonton, AB, Canada T6G 2B7

John Van Aerde, MD, PhD, FAAP, FRCPC
Departments of Pediatrics and Neonatology,
Stollery Children’s Hospital,
Edmonton, AB, Canada T6G 2B7

The first 20% of the full text of this article appears below.

To the Editor.—

Koo et al1 studied the effects of a palm olein formula versus a formula without palm olein on bone mineral content (BMC) and bone mineral density (BMD) in term infants. They suggest that matching the fatty acid profile of human milk by using palm olein in infant formulas may result in an unintended depression of bone mass accretion and may potentially be detrimental to optimum bone health. The article does not mention that infants fed human milk and other currently marketed formulas have BMC and BMD values well below either of the 2 study formulas and all are well within published normative values at both 3 and 6 months of age (see Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1. BMC of Study Milks (Bone Calcification Measurement)

 
It is important to provide the reader with a human milk control group, the comparative gold standard to which infant formulas are compared. Equally important is the large variation in published normative data for BMC and BMD of both human-milk–fed and formula-fed infants. The study by Koo . . . [Full Text of this Article]